Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 1998, Pages 255-258

  Boulieu, R ^a,b   Lehmann, B ^a,b   Salord, F ^b   Fisher, C ^b   Morlet, D ^c  

^a Institut des Sciences Pharmaceutiques et Biologiques   (France)

^b HÔPITAL NEUROLOGIQUE   (France)

^c INSERM   (France)

Author keywords

1 Hydroxymidazolam; Intensive care patients; Midazolam; Pharmacokinetics

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CARBAMAZEPINE; CREATININE; MIDAZOLAM;

ADOLESCENT; ADULT; AGED; AGING; CLINICAL ARTICLE; CONFERENCE PAPER; CREATININE CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE;

EID: 0031665722     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189348     Document Type: Conference Paper

References (13)

1. Dundee J.W., Halliday N.J., Harper K.W., Brogden R.N. (1984): Midazolam, a review of its pharmacological properties and therapeutic use. Drugs 28, 519-543.
2. Heizmann P., Eckert M., Zeigler W.H. (1983): Pharmacokinetics and bioavailability of midazolam in man. Br. J. Clin. Pharmacol. 16, 435-495.
3. Ziegler W.H., Schalch E., Leishman B., Eckert M. (1983): Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br. J. Clin. Pharmacol. 16, 63S-69S.
4. Oldenhof H., De Jong M., Steenhoek A., Janknegt R. (1988): Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability ? Clin. Pharmacol. Ther. 43, 263- 269.
5. Lehmann B., Boulieu R. (1995): Determination of midazolam and its unconjugated 1-hydroxy metabolite in human plasma by high performance liquid chromatography. J. Chromatogr., 674, 138-142
6. Gomeni C., Gomeni R., Siphar. (1987): An integrated computer system for statistical and pharmacokinetic data analysis. Proceedings of seventh International congress of Medical Informatics. Serrio A., OÆWoore R., Tardini A., Roger F. eds. European Federation of Medical Informatics, Rome.
7. Akaike H. (1974): A new look at the statistical identification model. IEEE Auto Control 19, 716-723.
8. Brown C.R., Sarnquist F.H., Canup C.A., Pedley T.A. (1979): Clinical electroencephalographic and pharmacokinetic studies of a water-soluble benzodiazepine, midazolam maleate. Anesthesiology 50, 467-470.
9. Allonen H., Ziegler G., Klotz U. (1981): Midazolam kinetics. Clin. Pharmacol. Ther., 30, 5, 653-660.
10. Michalk S., Moncorge C., Fichelle A. et al. (1988): Midazolam infusion for basal sedation in intensive care : absence of accumulation. Int. Care Med. 15, 37-41.
11. Malacrida R., Fritz M.E., Suter P.M., Crevoisier C. (1991): Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit. Care Med. 20, 1123- 1126.
12. Vree T.N., Shimoda M., Driessen J.J. et al. (1989): Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clin. Pharmacol. Ther. 46, 537-544.
13. Crevoisier C., Ziegler W.H., Cano J.P. et al. (1986): Relation between the pharmacokinetics and pharmacodynamics of intravenously administered midazolam, triazolam and their hydroxy metabolites. In : Second Congress of the Inter American Society for Clinical Pharmacology and Therapeutics, pp. 47.